FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies
Decision brief
Answer first · skim in under a minute
The FDA has extended the public comment period for its Real-Time Clinical Trials (RTCT) pilot and the associated Request for Information on AI-enabled optimization of early-phase trials. This move signals the agency's commitment to integrating AI into clinical trial oversight, with implications for drug development speed, cost, and regulatory strategy.
FDA real-time clinical trials moved from slogan to docket: after April 2026 proof-of-concept starts with AstraZeneca and Amgen, the agency extended the AI-enabled early-phase pilot RFI comment window to June 29, 2026—buying sponsors more time to shape selection rules.
Contents10 sections
Key Takeaways
- April 28, 2026: FDA announced RTCT proof-of-concept trials with AstraZeneca and Amgen plus an RFI for a broader summer pilot.
- Federal Register RFI (April 29, 2026) originally closed comments May 29, 2026 on AI-enabled early-phase optimization.
- FDA later extended that comment period to June 29, 2026.
- Agency timeline at launch: final pilot selection criteria in July; pilot selections in August.
What changed in the FDA real-time clinical trials timeline?
On April 28, 2026, FDA said it had started two proof-of-concept RTCTs and opened an RFI on scaling the approach. The agency planned to publish final selection criteria in July and finish pilot selections in August.
About a month later, FDA pushed the RFI deadline from May 29 to June 29, 2026—a 30-day extension that keeps industry comments alive while proof-of-concept data pipes are still being proven.
What did the April announcement actually authorize?
FDA’s press materials describe reviewers seeing endpoints and safety signals as investigators collect them, with data captured from electronic study records and analyzed on an automated platform. AstraZeneca’s Phase 2 TRAVERSE trial in treatment-naïve mantle cell lymphoma and Amgen’s Phase 1b STREAM-SCLC trial were named as the first proofs of concept.
FDA said it had already received and validated signals for AstraZeneca’s trial through Paradigm Health, establishing technical feasibility. That is infrastructure validation—not a new approval pathway for either drug.
What does the Federal Register RFI ask?
The April 29, 2026 Federal Register RFI on AI-enabled optimization of early-phase clinical trials seeks input on how AI can improve efficiency, speed, and quality of decision-making while preserving scientific standards.
It targets early-phase work under CDER, CBER, and the Oncology Center of Excellence, coordinated by the Deputy Chief Medical Officer in the Office of the Commissioner. Comments originally had to arrive by May 29, 2026, before the extension.
Why should BD and clinical operations teams care?
- Real-time feeds may compress information lag between site data entry and FDA questions—changing how medical monitors staff queries.
- AI tooling named in comments could become informal expectations for pilot eligibility.
- Cloud vendors and data processors become diligence parties alongside CROs.
Treat RTCT as a process experiment. It does not waive IND requirements, GCP, or labeling standards.
Where can sponsors still engage?
FDA held an industry information session on the RTCT RFI on May 15, 2026. The FDA meeting page for the May 15 session links the news release and RFI materials.
Even after the June 29 deadline, watch July selection-criteria documents—those will decide who gets into the broader pilot.
What remains unproven?
FDA has not published evidence that RTCTs shorten median approval clocks across a drug class. Proof-of-concept signal validation for one AstraZeneca trial does not prove scalability across therapeutic areas or Phase 3 complexity.
Do not claim that AI “will” cut development cost by a fixed percent. Cost claims need pilot metrics FDA has not yet finalized.
Also open: how confidential commercial information and patient-level datasets will be segmented when reviewers see live feeds; how inspection findings interact with real-time dashboards; and whether CDER and CBER will apply the same signal criteria. Sponsors should answer those questions in RFI comments rather than assume one oncology proof-of-concept sets the rule for every modality.
Until August pilot selections publish, treat RTCT participation as optional capacity planning—not a filing requirement for every IND.
Related NovaPharma coverage
- Vanda tradipitant FDA re-review update
- Cardiff Oncology pipeline and FDA meeting catalysts
- GLP-1 usage statistics
Frequently Asked Questions
What is FDA’s real-time clinical trials concept?
FDA describes RTCTs as trials where reviewers can see endpoints and safety signals in the cloud as data are collected, rather than waiting for a locked final package before any agency visibility.
When is the AI early-phase trials RFI comment deadline?
The original Federal Register RFI set comments due May 29, 2026. FDA later extended the comment period to June 29, 2026.
Which sponsors started proof-of-concept RTCTs?
FDA’s April 28, 2026 announcement named AstraZeneca’s Phase 2 TRAVERSE mantle cell lymphoma trial and Amgen’s Phase 1b STREAM-SCLC limited-stage small cell lung cancer trial.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
